Detalhe da pesquisa
1.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Br J Cancer
; 127(1): 79-83, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361918
2.
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol
; 159(1): 256-263, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712155
3.
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
Future Oncol
; 13(8): 679-693, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076966
4.
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.
Gynecol Oncol
; 133(3): 460-6, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24726614
5.
Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer.
Homeopathy
; 103(4): 232-8, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25439039
6.
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
JCO Clin Cancer Inform
; 8: e2300208, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364191
7.
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
J Gynecol Oncol
; 35(3): e34, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38216134
8.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
Gynecol Oncol
; 130(2): 289-94, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23694718
9.
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
JCO Clin Cancer Inform
; 7: e2200188, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075255
10.
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
EBioMedicine
; 89: 104477, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36801617
11.
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Cancer Chemother Pharmacol
; 91(5): 413-425, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37010549
12.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Cancer Chemother Pharmacol
; 91(5): 361-373, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36840749
13.
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Eur J Cancer
; 191: 112966, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37542936
14.
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel.
Cancers (Basel)
; 14(3)2022 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35159082
15.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
J Clin Oncol
; 40(34): 3965-3974, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36252167
16.
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Cancers (Basel)
; 14(1)2021 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008262
17.
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7).
JNCI Cancer Spectr
; 4(3): pkaa026, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32596636
18.
Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
Cancer Chemother Pharmacol
; 86(1): 15-24, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32500221
19.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
Clin Cancer Res
; 26(17): 4625-4632, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209570
20.
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Clin Cancer Res
; 25(17): 5342-5350, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30936122